Skip to content
WeighLab
Menu
Ranked #79 · Grade C

Ivy Rx review

Telehealth provider offering tiered compounded semaglutide and tirzepatide programs.

Visit Ivy Rx Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. See our disclosure.
Semaglutide
$175/mo (starting dose, compounded)
Tirzepatide
$275/mo (starting dose, compounded)
Coverage
All 50 states
Brand-name
Compounded only

Semaglutide · modeled / year

$2,100

Tirzepatide · modeled / year

$3,300

The Index scorecard

Ivy Rx scored on our six Cost-Efficiency Index factors. See the methodology.

Normalized Cost/Month62/100
Price Transparency78/100
Nationwide Access86/100
Formulation Options66/100
Clinical Oversight82/100
Contract Flexibility55/100

Where the value is

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

The tradeoffs

  • Limited public information on program details

The bottom line

Best for: Cost-first shoppers who want mainstream telehealth GLP-1 access. Telehealth provider offering tiered compounded semaglutide and tirzepatide programs.

Ranked #79 of 492 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.

Compare with other providers

All 491 other providers we've modeled, in Cost-Efficiency Index order. See the ranked alternatives to Ivy Rx.

The 24 programs nearest this one

Pricing, states and verification reflect Ivy Rx's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on Ivy Rx's site. Not medical advice; see our disclosure.

← Back to the value leaderboard